Medical News

RSS

Astellas Pharma extends all-cash tender offer of OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals to 11:59 p.m. New York City time on Friday, April 23, 2010, unless further extended.

31 Mar 2010

Roche Diagnostics' CoaguChek XS Plus system granted CLIA-waived status

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted CLIA-waived status to the CoaguChek® XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing.

From Roche Sequencing and Life Science 31 Mar 2010

Tips for avoiding ID theft while buying a home

IdentityTruth, the leading provider of a new breed of identity theft monitoring services to help consumers avoid identity theft and safeguard their privacy and identity, today is sharing its tips for avoiding ID theft when buying a home.

31 Mar 2010

Gore launches new consumer website to serve as patient resource on AAA

W. L. Gore & Associates announced the launch of a new consumer website, http://www.ultimatesaaave.com, which will serve as an enhanced patient resource on Abdominal Aortic Aneurysm.

31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

EvoLife Laboratories introduces cancer care products in USA

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, announced the launch of its products in USA.

31 Mar 2010

Rebooting and reprogramming the brain

Does the brain you were born with have to be the brain you end up with? If you can improve the function of every major organ in the body, why can't you upgrade the function of your brain? Those fundamental questions were the motivation that led Kelly Howell to create Brain Sync.

31 Mar 2010

Kaiser Permanente to deploy solar power systems at 15 facilities across the state

Committed to improving the health of the communities it serves, Kaiser Permanente has agreed to deploy 15 megawatts of solar power in a deal that will put solar power systems at 15 facilities across the state by the summer of 2011.

31 Mar 2010

New cakes and frostings may someday contain less fat and calories

Delicious new cakes and frostings may someday contain less fat and fewer calories, thanks to work by Agricultural Research Service (ARS) scientists such as Mukti Singh. She's based at the ARS National Center for Agricultural Utilization Research (NCAUR) in Peoria, Ill.

31 Mar 2010

CMS delays Medicare doctor pay cut until after congressional recess

"Doctors slated to have their Medicare reimbursements cut 21 percent on April 1 got a reprieve from the Centers for Medicare and Medicaid Services, which is delaying lowered payments until after Congress reconvenes," Bloomberg BusinessWeek reports.

31 Mar 2010

FDA accepts filing of Lux Biosciences' NDA for Luveniq and grants application priority review

Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the filing of the company's New Drug Application for Luveniq™ (oral voclosporin) and has granted the application priority review.

31 Mar 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

IGI Laboratories secures $1.55M Series C financing

IGI Laboratories, Inc. today announced that it has raised $1,550,000 through the private placement of Series C Convertible Preferred Stock.

31 Mar 2010

Nonprofit hospitals come under congressional scrutiny

A bipartisan effort is being made in Congress to crack down on nonprofit hospitals that refuse to offer charity care. Sen. Chuck Grassley (R-Iowa) and Rep. Bobby Rush (D-Ill.) are leading the effort.

31 Mar 2010

CryoLife files emergency motion for preliminary injunction against Medafor

CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it filed an emergency motion for a preliminary injunction against Medafor, Inc. in the United States District Court for the Northern District of Georgia, Atlanta division. CryoLife contends that Medafor is improperly attempting to terminate the exclusive distribution agreement ("EDA") between the parties, and CryoLife has requested that the Court enjoin Medafor from proceeding with the termination.

31 Mar 2010